The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This analysis illustrates the potential total cost of Pfizer and Moderna COVID-19 vaccines, based on their publicly-announced expected prices, once they enter the U.S. commercial market. It compares the average price paid by the federal government for the COVID-19 bivalent boosters to the estimated average commercial prices across different scenarios.
In this commentary for Barron's, KFF's Cynthia Cox and Jennifer Kates explore what will happen with costs to COVID-19 vaccines for people with and without insurance once the relevant public health emergency ends on May 11.
This survey finds that nearly four-in-ten adults say their households were recently sick with COVID-19, the Flu, or RSV, and news of the viruses is making many more likely to wear masks and take other precautions. It also explores uptake of the new bivalent booster, why many vaccinated adults have not gotten it, and enthusiasm for another shot among those who have.
Booster update remains modest; half of those already boosted are waiting for updated CDC guidelines to get another dose Nearly four in ten (38%) people say their households were affected by this winter's triple threat of viruses, with someone getting sick with the flu, COVID-19, or respiratory syncytial virus (RSV), and nearly half (46%) say the news of these three viruses spreading has made them more likely to wear masks or take other precautions to…
This post provides an overview of how health care coverage and access will and won’t change when the public health emergency ends on May 11, including a discussion of COVID-19 vaccines, tests, and treatments, and telemedicine.
Amid controversies around the COVID-19 vaccine and growing distrust of public health authorities, more than four in ten Republicans and Republican-leaning independents, and a third of parents, now say they oppose requiring children in public schools to receive some childhood vaccines, up since 2019, a new KFF COVID-19 Vaccine Monitor survey finds. Overall, nearly three in ten adults (28%) nationally now say that parents should be able to decide not to vaccinate their children for…
This Vaccine Monitor survey finds that almost three in ten adults now say that parents should be able to decide not to vaccinate their school-age children for measles and other childhood illness, up since 2019 before the COVID-19 pandemic. It also explores uptake of the new bivalent booster, and why many vaccinated adults have not gotten it.
If the federal government runs out of money to purchase COVID-19 vaccines, the per-dose price likely would skyrocket and could increase spending on vaccines by billions of dollars a year, a new KFF analysis finds. To date, the federal government has spent more than $30 billion on COVID-19 vaccines to encourage their development, guarantee a market, and ensure that the public can access them at no charge. The Biden administration has said it can no…
This post explores why the share of COVID-19 deaths among those who are vaccinated has risen, Factors include a rising share of the population that is vaccinated, waning immune protection and low uptake of boosters, and changes in immunity among the unvaccinated.
In this Issue Brief we review and assess the COVAX Humanitarian Buffer mechanism, which is part of the effort to share Covid vaccines globally. The Buffer is intended to direct vaccines to vulnerable people like refugees and others facing humanitarian emergencies during the pandemic, and was supported by the US and many other donors and organizations. However, it faced many challenges such as liability and indemnification issues for using newly developed vaccines, restricted access to…
© 2026 KFF